Advances in the Treatment of Relapsed and Refractory Multiple Myeloma: Novel Agents, Immunotherapies and Beyond
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 43612
Special Issue Editors
Interests: multiple myeloma; breast cancer; signal transduction; tumor microenvironment; angiogenesis; bone disease; targeted therapy; apoptosis
Special Issues, Collections and Topics in MDPI journals
Interests: myeloma; drug development; treatment sequences; immunology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Despite the challenges and odds imposed by the COVID-19 pandemic, therapeutic progress continues to be made in multiple myeloma (MM). New approvals in 2020 include the CD38 monoclonal antibody (mAb) isatuximab in combination with pomalidomide and dexamethasone; the combination of daratumumab with carfilzomib and dexamethasone; and the antibody drug conjugate (ADC) belantamab-mafodotin, for the treatment of relapsed/refractory (RR)MM; and s.c. daratumumab for all lines of therapy.
The combinatorial use of IMiDs, proteasome inhibitors, and monoclonal antibodies (mAbs), cornerstones of current MM therapy, has revolutionized MM treatment strategies and significantly improved patient survival. Nevertheless, almost all MM patients who have received initial therapy eventually relapse, with responses becoming progressively shorter with each line of therapy. Continuous clinical and basic research to identify novel therapeutic targets, optimal drug combinations and their timing dependent on disease, prior treatment and patient characteristics in a cost-effective and safe manner are therefore needed.
In this issue, eminent experts in the field of MM will summarize the most recent therapeutic developments, and offer evidence-based recommendations for combinatorial treatment approaches in RRMM patients. Among other topics, current strategies to treat MM patients refractory to lenalidomide, PIs, and/or mAbs in early or late relapse; and high-risk patients will be discussed. Moreover, promising biomarkers for drug resistance, therapy response, and tolerability using gene expression and proteomic profiling, as well as FACS analysis will be summarized. In addition, authors will present data on agents whose approval is expected during the next months; and on the impact of the “next-generation” of immunotherapies, chimeric antigen receptor T cells (CAR T cells), bispecific T cell engagers (BiTEs) and ADCs, as well as vaccines, in particular.
Prof. Klaus Podar
Prof. Xavier Leleu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- myeloma relapse setting
- drug development
- treatment sequences
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.